

Iain S McGregor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6849087/publications.pdf>

Version: 2024-02-01

279
papers

15,629
citations

13099

68
h-index

26613

107
g-index

285
all docs

285
docs citations

285
times ranked

11584
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Possible Anticonvulsant Effect of Δ^9 -Tetrahydrocannabinolic Acid in Murine Seizure Models. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 46-57.	2.9	13
2	Orally administered cannabidiol does not produce false-positive tests for Δ^9 -tetrahydrocannabinol on the Securetec DrugWipe [®] 5S or Dräger DrugTest [®] 5000. <i>Drug Testing and Analysis</i> , 2022, 14, 137-143.	2.6	11
3	Structure-activity relationships of valine, <i>tert</i> -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. <i>RSC Medicinal Chemistry</i> , 2022, 13, 156-174.	3.9	11
4	Are blood and oral fluid Δ^9 -tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 134, 104433.	6.1	15
5	Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the "PELICAN" study. <i>Epilepsy and Behavior</i> , 2022, 127, 108496.	1.7	7
6	Olivetolic acid, a cannabinoid precursor in <i>Cannabis sativa</i> , but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. <i>Journal of Cannabis Research</i> , 2022, 4, 2.	3.2	6
7	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. <i>Drug and Alcohol Review</i> , 2022, 41, 1095-1108.	2.1	11
8	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. <i>Sports Medicine - Open</i> , 2022, 8, 27.	3.1	10
9	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109388.	3.2	1
10	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. <i>Addiction Biology</i> , 2022, 27, e13125.	2.6	18
11	Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. <i>Psychopharmacology</i> , 2022, 239, 1593-1603.	3.1	2
12	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca_v3) Inhibitors. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1395-1409.	3.5	4
13	Defining Steric Requirements at CB_1 and CB_2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1281-1295.	3.5	6
14	Cannabinoids, Insomnia, and Other Sleep Disorders. <i>Chest</i> , 2022, 162, 452-465.	0.8	14
15	Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	19
16	Response to: "Cannabis use before safety sensitive work: What delay is prudent?" TM . <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 137, 104684.	6.1	1
17	Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats. <i>Neuropsychopharmacology</i> , 2022, 47, 1561-1573.	5.4	5
18	Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2022, 36, 1338-1349.	4.0	23

#	ARTICLE	IF	CITATIONS
19	A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 422-424.	1.4	5
20	A nutraceutical product, extracted from <i>Cannabis sativa</i> , modulates voltage-gated sodium channel function. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	7
21	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. <i>Neuropharmacology</i> , 2021, 182, 108371.	4.1	3
22	A validated method for the simultaneous quantification of cannabidiol, Δ^9 -tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial. <i>Drug Testing and Analysis</i> , 2021, 13, 614-627.	2.6	14
23	The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. <i>Journal of Sleep Research</i> , 2021, 30, e13211.	3.2	3
24	The failings of <i>per se</i> limits to detect cannabis-induced driving impairment: Results from a simulated driving study. <i>Traffic Injury Prevention</i> , 2021, 22, 102-107.	1.4	27
25	Driving Impairment Following Vaporization of Cannabis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1226.	7.4	1
26	Cannabichromene and Δ^9 -Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by <i>in Silico</i> and <i>in Vitro</i> Screening. <i>Journal of Natural Products</i> , 2021, 84, 1469-1477.	3.0	6
27	The effect of COVID19 pandemic restrictions on an urban rodent population. <i>Scientific Reports</i> , 2021, 11, 12957.	3.3	12
28	Medical cannabis and driving. <i>Australian Journal of General Practice</i> , 2021, 50, 357-362.	0.8	19
29	Determining the magnitude and duration of acute Δ^9 -tetrahydrocannabinol (Δ^9 -THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 175-193.	6.1	79
30	The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. <i>Journal of Cannabis Research</i> , 2021, 3, 33.	3.2	0
31	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. <i>British Journal of Pharmacology</i> , 2021, 178, 4826-4841.	5.4	32
32	Citalopram and Cannabidiol. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 525-533.	1.4	24
33	Medicinal cannabis in the treatment of chronic pain. <i>Australian Journal of General Practice</i> , 2021, 50, 724-732.	0.8	15
34	Medicinal cannabis and driving: the intersection of health and road safety policy. <i>International Journal of Drug Policy</i> , 2021, 97, 103307.	3.3	16
35	Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. <i>ACS Chemical Neuroscience</i> , 2021, 12, 330-339.	3.5	28
36	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4020-4036.	3.5	7

#	ARTICLE	IF	CITATIONS
37	Access to cannabidiol without a prescription: A cross-country comparison and analysis. <i>International Journal of Drug Policy</i> , 2020, 85, 102935.	3.3	50
38	Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. <i>Crohn's & Colitis</i> 360, 2020, 2, .	1.1	8
39	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. <i>Accident Analysis and Prevention</i> , 2020, 148, 105784.	5.7	24
40	Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2020, 2, .	1.1	3
41	The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol. <i>Human Psychopharmacology</i> , 2020, 35, e2749.	1.5	13
42	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108220.	3.2	19
43	Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. <i>Sleep Medicine Reviews</i> , 2020, 53, 101339.	8.5	96
44	Cannabidiol (CBD) and Δ^9 -tetrahydrocannabinol (THC) for chronic insomnia disorder (â€CANSLEEPâ€™ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. <i>BMJ Open</i> , 2020, 10, e034421.	1.9	24
45	Terpenoids Commonly Found in <i>Cannabis sativa</i> Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 305-317.	2.9	38
46	Interactions between cannabidiol and Δ^9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. <i>British Journal of Pharmacology</i> , 2020, 177, 4261-4274.	5.4	30
47	Medical cannabis use in the Australian community following introduction of legal access: the 2018â€C2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). <i>Harm Reduction Journal</i> , 2020, 17, 37.	3.2	72
48	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 193, 172918.	2.9	11
49	Effect of Cannabidiol and Δ^9 -Tetrahydrocannabinol on Driving Performance. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2177.	7.4	106
50	Gain-of-function <i>GABRB3</i> variants identified in vigabatrin-hypersensitive epileptic encephalopathies. <i>Brain Communications</i> , 2020, 2, fcaa162.	3.3	21
51	Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. <i>Sports Medicine - Open</i> , 2020, 6, 27.	3.1	34
52	Prescribing medicinal cannabis. <i>Australian Prescriber</i> , 2020, 43, 152-159.	1.0	40
53	Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. <i>Forensic Toxicology</i> , 2019, 37, 17-26.	2.4	28
54	Synthesis and pharmacology of new psychoactive substance 5Fâ€CUMYLâ€P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5Fâ€CUMYLâ€PICA and 5Fâ€CUMYLâ€PINACA. <i>Drug Testing and Analysis</i> , 2019, 11, 279-291.	2.6	45

#	ARTICLE	IF	CITATIONS
55	Cannabichromene is a cannabinoid CB ₂ receptor agonist. <i>British Journal of Pharmacology</i> , 2019, 176, 4537-4547.	5.4	68
56	Absence of Entourage: Terpenoids Commonly Found in <i>Cannabis sativa</i> Do Not Modulate the Functional Activity of Δ^9 -THC at Human CB ₁ and CB ₂ Receptors. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 165-176.	2.9	84
57	Nabiximols for the Treatment of Cannabis Dependence. <i>JAMA Internal Medicine</i> , 2019, 179, 1242.	5.1	68
58	Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. <i>Frontiers in Ecology and Evolution</i> , 2019, 7, .	2.2	29
59	Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. <i>Journal of Natural Products</i> , 2019, 82, 3047-3055.	3.0	77
60	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. <i>Epilepsia</i> , 2019, 60, 2224-2234.	5.1	103
61	Detection of Δ^9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. <i>Drug Testing and Analysis</i> , 2019, 11, 1486-1497.	2.6	32
62	Dark Classics in Chemical Neuroscience: Δ^9 -Tetrahydrocannabinol. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2160-2175.	3.5	55
63	CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. <i>Frontiers in Pharmacology</i> , 2019, 10, 595.	3.5	32
64	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724.	3.1	130
65	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. <i>Journal of Biological Chemistry</i> , 2019, 294, 6157-6171.	3.4	20
66	The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F Δ -PICA, 5F Δ -PINACA, and their analogs. <i>Drug Testing and Analysis</i> , 2019, 11, 976-989.	2.6	17
67	Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis. <i>Scientific Reports</i> , 2019, 9, 16189.	3.3	9
68	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 414-422.	2.5	33
69	The chemistry and pharmacology of synthetic cannabinoid SDB Δ and its regioisomeric fluorinated and methoxylated analogs. <i>Drug Testing and Analysis</i> , 2018, 10, 1099-1109.	2.6	12
70	The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. <i>Neuropharmacology</i> , 2018, 133, 1-11.	4.1	37
71	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 437-446.	2.5	69
72	Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding. <i>Psychoneuroendocrinology</i> , 2018, 87, 83-92.	2.7	50

#	ARTICLE	IF	CITATIONS
73	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MNâ€18. <i>Drug Testing and Analysis</i> , 2018, 10, 137-147.	2.6	11
74	Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. <i>Journal of Psychopharmacology</i> , 2018, 32, 1369-1378.	4.0	56
75	Cannabis use and non-cancer chronic pain. <i>Lancet Public Health</i> , The, 2018, 3, e467.	10.0	0
76	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018, 8, e020745.	1.9	16
77	Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. <i>BMC Psychiatry</i> , 2018, 18, 140.	2.6	17
78	Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. <i>Scientific Reports</i> , 2018, 8, 10154.	3.3	41
79	Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. <i>BMJ Open</i> , 2018, 8, e022101.	1.9	94
80	Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMSâ€16). <i>Medical Journal of Australia</i> , 2018, 209, 211-216.	1.7	66
81	Oxytocin inhibits ethanol consumption and ethanolâ€induced dopamine release in the nucleus accumbens. <i>Addiction Biology</i> , 2017, 22, 702-711.	2.6	78
82	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. <i>Journal of Psychopharmacology</i> , 2017, 31, 757-769.	4.0	21
83	The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. <i>Pharmacological Research</i> , 2017, 119, 358-370.	7.1	164
84	An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. <i>Epilepsy and Behavior</i> , 2017, 70, 334-340.	1.7	55
85	In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. <i>Forensic Toxicology</i> , 2017, 35, 333-347.	2.4	35
86	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2159-2167.	3.5	53
87	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. <i>Mental Health and Physical Activity</i> , 2017, 13, 57-67.	1.8	5
88	Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 9-15.	4.8	21
89	Urinary cannabinoid levels during nabiximols (Sativexâ€)â€medicated inpatient cannabis withdrawal. <i>Forensic Toxicology</i> , 2017, 35, 33-44.	2.4	19
90	ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. <i>PeerJ</i> , 2016, 4, e2081.	2.0	38

#	ARTICLE	IF	CITATIONS
91	A Nose for Death: Integrating Trophic and Informational Networks for Conservation and Management. <i>Frontiers in Ecology and Evolution</i> , 2016, 4, .	2.2	23
92	Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine-seeking behaviour in rats. <i>Addiction Biology</i> , 2016, 21, 316-325.	2.6	69
93	Adolescent pre-treatment with oxytocin protects against adult methamphetamine-seeking behavior in female rats. <i>Addiction Biology</i> , 2016, 21, 304-315.	2.6	43
94	Pharmacology of Valinate and <i>tert</i> -Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1241-1254.	3.5	214
95	Behavioral and cognitive data in mice with different tryptophan-metabolizing enzymes knocked out. <i>Data in Brief</i> , 2016, 9, 275-287.	1.0	4
96	Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. <i>Brain Research Bulletin</i> , 2016, 127, 208-218.	3.0	19
97	MDMA (Ecstasy™), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 150-151, 115-123.	2.9	13
98	Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine. <i>Brain Research Bulletin</i> , 2016, 121, 246-254.	3.0	6
99	Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. <i>Behavioural Brain Research</i> , 2016, 312, 102-117.	2.2	52
100	Altered behaviour and cognitive function following combined deletion of Toll-like receptors 2 and 4 in mice. <i>Behavioural Brain Research</i> , 2016, 303, 1-8.	2.2	12
101	Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain. <i>Neurochemical Research</i> , 2016, 41, 385-397.	3.3	20
102	Antibody-induced neutrophil depletion prior to the onset of pneumococcal meningitis influences long-term neurological complications in mice. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 68-83.	4.1	14
103	Cortisol response and psychological distress predict susceptibility to false memories for a trauma film. <i>Memory</i> , 2016, 24, 1278-1286.	1.7	1
104	The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1153-1162.	2.6	16
105	Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. <i>Forensic Toxicology</i> , 2015, 33, 355-366.	2.4	26
106	Oxytocin prevents ethanol actions at γ subunit-containing GABA _A receptors and attenuates ethanol-induced motor impairment in rats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3104-3109.	7.1	70
107	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1546-1559.	3.5	202
108	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1445-1458.	3.5	167

#	ARTICLE	IF	CITATIONS
109	WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. <i>Psychopharmacology</i> , 2015, 232, 2659-2667.	3.1	19
110	Oxytocin and MDMA (â€ˆEcstasyâ€™™) enhance social reward in rats. <i>Psychopharmacology</i> , 2015, 232, 2631-2641.	3.1	35
111	Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal. <i>JAMA Psychiatry</i> , 2014, 71, 281.	11.0	209
112	Oxytocin and vasopressin modulate the social response to threat: a preclinical study. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1621-1633.	2.1	50
113	A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 2232-2239.	1.2	103
114	Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009â€™2012: Focus on children, adolescents and prescriber specialty. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 917-931.	2.3	84
115	The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis. <i>Brain, Behavior, and Immunity</i> , 2014, 40, 252-268.	4.1	44
116	Inhaled vasopressin increases sociability and reduces body temperature and heart rate in rats. <i>Psychoneuroendocrinology</i> , 2014, 46, 46-51.	2.7	18
117	Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. <i>Hormones and Behavior</i> , 2014, 65, 488-496.	2.1	31
118	Changes in cigarette and alcohol use during cannabis abstinence. <i>Drug and Alcohol Dependence</i> , 2014, 138, 54-60.	3.2	46
119	The First CNS-Active Carborane: A Novel P2X ₇ Receptor Antagonist with Antidepressant Activity. <i>ACS Chemical Neuroscience</i> , 2014, 5, 335-339.	3.5	118
120	Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 2868-2887.	5.4	70
121	Regional Fos-expression induced by Î³-hydroxybutyrate (GHB): Comparison with Î³-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. <i>Neuroscience</i> , 2014, 277, 700-715.	2.3	7
122	Active coping toward predatory stress is associated with lower corticosterone and progesterone plasma levels and decreased methylation in the medial amygdala vasopressin system. <i>Hormones and Behavior</i> , 2014, 66, 561-566.	2.1	34
123	Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. <i>Tetrahedron Letters</i> , 2014, 55, 4568-4571.	1.4	8
124	Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. <i>Psychopharmacology</i> , 2014, 231, 3987-3996.	3.1	7
125	Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. <i>Psychopharmacology</i> , 2014, 231, 4623-4636.	3.1	29
126	Neuroadaptations in the Striatal Proteome of the Rat Following Prolonged Excessive Sucrose Intake. <i>Neurochemical Research</i> , 2014, 39, 815-824.	3.3	24

#	ARTICLE	IF	CITATIONS
127	The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis. <i>Behavioural Brain Research</i> , 2014, 270, 179-195.	2.2	10
128	P2X7 in Bipolar and Depressive Disorders. , 2014, , 635-661.		2
129	Driving on ice: impaired driving skills in current methamphetamine users. <i>Psychopharmacology</i> , 2013, 225, 161-172.	3.1	17
130	A brief history of oxytocin and its role in modulating psychostimulant effects. <i>Journal of Psychopharmacology</i> , 2013, 27, 231-247.	4.0	90
131	High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. <i>Journal of Psychopharmacology</i> , 2013, 27, 823-836.	4.0	82
132	Exercise increases plasma THC concentrations in regular cannabis users. <i>Drug and Alcohol Dependence</i> , 2013, 133, 763-767.	3.2	34
133	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. <i>Neuropsychopharmacology</i> , 2013, 38, 2249-2259.	5.4	112
134	Give me a hi-5! An additional version of the h-index. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1119-1123.	2.3	3
135	Heart rate variability predicts alcohol craving in alcohol dependent outpatients: Further evidence for HRV as a psychophysiological marker of self-regulation. <i>Drug and Alcohol Dependence</i> , 2013, 132, 395-398.	3.2	68
136	A Meta-Analysis on the Impact of Alcohol Dependence on Short-Term Resting-State Heart Rate Variability: Implications for Cardiovascular Risk. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E23-9.	2.4	89
137	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1081-1092.	3.5	80
138	Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 74-87.	2.3	187
139	Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile. <i>PLoS ONE</i> , 2013, 8, e70052.	2.5	161
140	Moderate alcohol intake is related to increased heart rate variability in young adults: Implications for health and well-being. <i>Psychophysiology</i> , 2013, 50, 1202-1208.	2.4	36
141	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 163-175.	2.1	69
142	Defensive Aggregation (Huddling) in <i>Rattus Norvegicus</i> toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. <i>PLoS ONE</i> , 2013, 8, e68483.	2.5	45
143	Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons. <i>Frontiers in Pharmacology</i> , 2013, 4, 86.	3.5	19
144	Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 15.	3.7	31

#	ARTICLE	IF	CITATIONS
145	Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users.. <i>Experimental and Clinical Psychopharmacology</i> , 2012, 20, 497-503.	1.8	28
146	Long-term daily access to alcohol alters dopamine-related synthesis and signaling proteins in the rat striatum. <i>Neurochemistry International</i> , 2012, 61, 1280-1288.	3.8	25
147	Regional c-Fos and FosB/Î”FosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. <i>Neuroscience</i> , 2012, 206, 100-114.	2.3	48
148	Breaking the loop: Oxytocin as a potential treatment for drug addiction. <i>Hormones and Behavior</i> , 2012, 61, 331-339.	2.1	236
149	Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. <i>Behavioural Brain Research</i> , 2012, 228, 185-193.	2.2	88
150	Aggregation in quads but not pairs of rats exposed to cat odor or bright light. <i>Behavioural Processes</i> , 2012, 90, 331-336.	1.1	34
151	Rubbings deposited by cats elicit defensive behavior in rats. <i>Physiology and Behavior</i> , 2012, 107, 711-718.	2.1	15
152	Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. <i>PLoS ONE</i> , 2012, 7, e34129.	2.5	80
153	Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion. <i>PLoS ONE</i> , 2012, 7, e45473.	2.5	56
154	Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells. <i>Neurochemical Research</i> , 2012, 37, 1649-1659.	3.3	19
155	Mephedrone (4â€methylmethcathinone, â€meowâ€™): acute behavioural effects and distribution of Fos expression in adolescent rats. <i>Addiction Biology</i> , 2012, 17, 409-422.	2.6	77
156	The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptorâ€Binding Profile, Prosocial Effects and Distribution of câ€Fos Expression in Adolescent Rats. <i>Journal of Neuroendocrinology</i> , 2012, 24, 1012-1029.	2.6	63
157	MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. <i>Brain Research Bulletin</i> , 2011, 86, 65-73.	3.0	41
158	Predatory threat induces huddling in adolescent rats and residual changes in early adulthood suggestive of increased resilience. <i>Behavioural Brain Research</i> , 2011, 225, 405-414.	2.2	47
159	â€When an old rat smells a catâ€™: A decline in defense-related, but not accessory olfactory, Fos expression in aged rats. <i>Neurobiology of Aging</i> , 2011, 32, 737-749.	3.1	18
160	Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. <i>Neuroscience</i> , 2011, 189, 170-177.	2.3	95
161	Disruptive effects of the prototypical cannabinoid Î”9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. <i>Behavioural Pharmacology</i> , 2011, 22, 191-202.	1.7	29
162	Cannabidiol potentiates Î”9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. <i>Psychopharmacology</i> , 2011, 218, 443-457.	3.1	166

#	ARTICLE	IF	CITATIONS
163	Beer promotes high levels of alcohol intake in adolescent and adult alcohol-preferring rats. <i>Alcohol</i> , 2011, 45, 485-498.	1.7	16
164	The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 631-643.	2.1	66
165	Antidepressants and adolescent brain development. <i>Future Neurology</i> , 2011, 6, 783-808.	0.5	12
166	The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia. <i>Neuropsychopharmacology</i> , 2011, 36, 1349-1358.	5.4	63
167	Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 491-504.	2.1	31
168	Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats. <i>PLoS ONE</i> , 2011, 6, e27237.	2.5	123
169	Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ -hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. <i>Psychopharmacology</i> , 2010, 212, 663-674.	3.1	28
170	Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. <i>Addiction Biology</i> , 2010, 15, 448-463.	2.6	119
171	A long hangover from party drugs: Residual proteomic changes in the hippocampus of rats 8 weeks after γ -hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. <i>Neurochemistry International</i> , 2010, 56, 871-877.	3.8	23
172	Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety. <i>Life Sciences</i> , 2010, 87, 572-578.	4.3	25
173	Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. <i>Neuropharmacology</i> , 2010, 58, 38-43.	4.1	138
174	A behavioural comparison of acute and chronic Δ^9 -tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 861-876.	2.1	167
175	Involvement of hypothalamic peptides in the anorectic action of the CB ₁ receptor antagonist rimonabant (SR 141716). <i>European Journal of Neuroscience</i> , 2009, 29, 2207-2216.	2.6	36
176	Proteomic Analysis Demonstrates Adolescent Vulnerability to Lasting Hippocampal Changes Following Chronic Alcohol Consumption. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 86-94.	2.4	45
177	Reintoxication: the release of fat-stored Δ^9 -tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. <i>British Journal of Pharmacology</i> , 2009, 158, 1330-1337.	5.4	72
178	Differential protein expression in the corpus callosum (body) of human alcoholic brain. <i>Journal of Neurochemistry</i> , 2009, 110, 486-495.	3.9	18
179	Intermittent access to beer promotes binge-like drinking in adolescent but not adult Wistar rats. <i>Alcohol</i> , 2009, 43, 305-314.	1.7	39
180	Sedative and hypothermic effects of γ -hydroxybutyrate (GHB) in rats alone and in combination with other drugs: Assessment using biotelemetry. <i>Drug and Alcohol Dependence</i> , 2009, 103, 137-147.	3.2	20

#	ARTICLE	IF	CITATIONS
181	The distribution of $\hat{1}^3$ -hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen. <i>Neuroscience</i> , 2009, 158, 441-455.	2.3	54
182	Comparative proteomics in the corpus callosal sub-regions of postmortem human brain. <i>Neurochemistry International</i> , 2009, 55, 483-490.	3.8	13
183	Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells. <i>Neurochemistry International</i> , 2009, 55, 558-565.	3.8	16
184	Long-lasting FosB/ $\hat{1}$ FosB immunoreactivity in the rat brain after repeated cat odor exposure. <i>Neuroscience Letters</i> , 2009, 462, 157-161.	2.1	27
185	Rats discriminate individual cats by their odor: Possible involvement of the accessory olfactory system. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1209-1217.	6.1	34
186	From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?. <i>British Journal of Pharmacology</i> , 2008, 154, 358-368.	5.4	153
187	Adolescent Rats Find Repeated $\hat{1}$ ⁹ -THC Less Aversive Than Adult Rats but Display Greater Residual Cognitive Deficits and Changes in Hippocampal Protein Expression Following Exposure. <i>Neuropsychopharmacology</i> , 2008, 33, 1113-1126.	5.4	271
188	Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization. <i>Neuroscience Letters</i> , 2008, 435, 113-119.	2.1	31
189	Cat odor, but not trimethylthiazoline (fox odor), activates accessory olfactory and defense-related brain regions in rats. <i>Neuroscience</i> , 2008, 151, 937-947.	2.3	99
190	Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1013-1021.	4.8	19
191	High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats. <i>Journal of Psychopharmacology</i> , 2008, 22, 100-110.	4.0	16
192	International conference on memory (ICOM-4), University of New South Wales, Sydney, Australia, 16-21 July 2006 Ecstasy/MDMA and Memory Symposium. <i>Journal of Psychopharmacology</i> , 2007, 21, 895-897.	4.0	2
193	Benzodiazepines impair the acquisition and reversal of olfactory go/no-go discriminations in rats.. <i>Behavioral Neuroscience</i> , 2007, 121, 527-534.	1.2	10
194	A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (ecstasy). <i>Neuroscience</i> , 2007, 146, 509-514.	2.3	207
195	Heterozygous neuregulin 1 mice display greater baseline and $\hat{1}$ ⁹ -tetrahydrocannabinol-induced c-Fos expression. <i>Neuroscience</i> , 2007, 149, 861-870.	2.3	72
196	Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. <i>Drug and Alcohol Dependence</i> , 2007, 86, 183-190.	3.2	60
197	Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization. <i>Proteomics</i> , 2007, 7, 1131-1139.	2.2	40
198	Topiramate Moderately Reduces the Motivation to Consume Alcohol and Has a Marked Antidepressant Effect in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 1900-1907.	2.4	47

#	ARTICLE	IF	CITATIONS
199	MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. <i>Drug and Alcohol Review</i> , 2007, 26, 9-15.	2.1	41
200	Inflammation and Breakdown of the Blood-Retinal Barrier During Physiological Aging in the Rat Retina: A Model for CNS Aging. <i>Microcirculation</i> , 2007, 14, 63-76.	1.8	70
201	Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. <i>Journal of Psychopharmacology</i> , 2006, 20, 611-621.	4.0	213
202	Defensive responses of Wistar and Sprague-Dawley rats to cat odour and TMT. <i>Behavioural Brain Research</i> , 2006, 172, 351-354.	2.2	58
203	Perinatal Exposure to δ^9 -Tetrahydrocannabinol Alters Heroin-Induced Place Conditioning and Fos-Immunoreactivity. <i>Neuropsychopharmacology</i> , 2006, 31, 58-69.	5.4	43
204	Protein expression profile in the striatum of acute methamphetamine-treated rats. <i>Brain Research</i> , 2006, 1097, 19-25.	2.2	66
205	Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 454-463.	2.9	24
206	Asymmetric Suppression of Components in Binary Aldehyde Mixtures: Behavioral Studies in the Laboratory Rat. <i>Chemical Senses</i> , 2006, 32, 191-199.	2.0	12
207	Fear, risk assessment, and playfulness in the juvenile rat.. <i>Behavioral Neuroscience</i> , 2006, 120, 49-59.	1.2	45
208	TMT-induced autonomic and behavioral changes and the neural basis of its processing. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1145-1156.	6.1	141
209	Defensive behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1121-1122.	6.1	4
210	The effects of predator odors in mammalian prey species: A review of field and laboratory studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1123-1144.	6.1	685
211	Cocaine and heroin (speedball) self-administration: the involvement of nucleus accumbens dopamine and $\delta^1/4$ -opiate, but not δ^1 -opiate receptors. <i>Psychopharmacology</i> , 2005, 180, 21-32.	3.1	33
212	Neural activation during cat odor-induced conditioned fear and trial 2 fear in rats. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1265-1277.	6.1	61
213	δ^9 -THC REINSTATES BEER- AND SUCROSE-SEEKING BEHAVIOUR IN ABSTINENT RATS: COMPARISON WITH MIDAZOLAM, FOOD DEPRIVATION AND PREDATOR ODOUR. <i>Alcohol and Alcoholism</i> , 2005, 40, 35-45.	1.6	47
214	Co-administration of THC and MDMA (Ecstasy) Synergistically Disrupts Memory in Rats. <i>Neuropsychopharmacology</i> , 2005, 30, 1475-1482.	5.4	21
215	Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 648-657.	4.8	61
216	MDMA (Ecstasy) and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats. <i>Neuropharmacology</i> , 2005, 49, 195-207.	4.1	42

#	ARTICLE	IF	CITATIONS
217	Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of δ^9 -tetrahydrocannabinol. <i>Neuropharmacology</i> , 2005, 49, 1101-1109.	4.1	73
218	Chronic repetitive transcranial magnetic stimulation is antidepressant but not anxiolytic in rat models of anxiety and depression. <i>Psychiatry Research</i> , 2005, 137, 113-121.	3.3	21
219	Chronic Fluoxetine Treatment Partly Attenuates the Long-Term Anxiety and Depressive Symptoms Induced by MDMA (‘Ecstasy’) in Rats. <i>Neuropsychopharmacology</i> , 2004, 29, 694-704.	5.4	79
220	Neural Correlates of Cat Odor-Induced Anxiety in Rats: Region-Specific Effects of the Benzodiazepine Midazolam. <i>Journal of Neuroscience</i> , 2004, 24, 4134-4144.	3.6	200
221	Preexposure to MDMA (‘Ecstasy’) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 79, 331-342.	2.9	17
222	The dopamine receptor antagonist SCH 23390 attenuates feeding induced by δ^9 -tetrahydrocannabinol. <i>Brain Research</i> , 2004, 1020, 188-195.	2.2	48
223	A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. <i>Brain Research</i> , 2004, 1026, 244-253.	2.2	77
224	Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. <i>Psychopharmacology</i> , 2004, 173, 210-216.	3.1	52
225	MDMA (‘ecstasy’), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. <i>Psychopharmacology</i> , 2004, 173, 318-325.	3.1	72
226	Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 804, 319-326.	2.3	38
227	Cyclooxygenase-2 in the Pathogenesis of Murine Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 2004, 189, 751-758.	4.0	45
228	Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. <i>Journal of Psychopharmacology</i> , 2004, 18, 502-508.	4.0	215
229	Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (‘Ecstasy’) in rats. <i>Neuropharmacology</i> , 2004, 46, 954-965.	4.1	52
230	Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. <i>Neuropharmacology</i> , 2004, 47, 593-603.	4.1	58
231	Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. <i>Neuroscience Letters</i> , 2004, 354, 217-220.	2.1	94
232	Rats on the grog: Novel pharmacotherapies for alcohol craving. <i>Addictive Behaviors</i> , 2004, 29, 1341-1357.	3.0	34
233	Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. <i>Journal of Psychopharmacology</i> , 2004, 18, 502-508.	4.0	238
234	The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. <i>Psychopharmacology</i> , 2003, 166, 51-60.	3.1	41

#	ARTICLE	IF	CITATIONS
235	The cannabinoid receptor antagonist SR141716 attenuates overfeeding induced by systemic or intracranial morphine. <i>Psychopharmacology</i> , 2003, 168, 314-323.	3.1	40
236	Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. <i>Psychopharmacology</i> , 2003, 168, 465-474.	3.1	79
237	Heat increases 3,4-methylenedioxyamphetamine self-administration and social effects in rats. <i>European Journal of Pharmacology</i> , 2003, 482, 339-341.	3.5	68
238	Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. <i>European Journal of Pharmacology</i> , 2003, 465, 105-114.	3.5	57
239	Increased Anxiety 3 Months after Brief Exposure to MDMA (Ecstasy) in Rats: Association with Altered 5-HT Transporter and Receptor Density. <i>Neuropsychopharmacology</i> , 2003, 28, 1472-1484.	5.4	99
240	Not all predator odours are equal: cat odour but not 2,4,5 trimethylthiazoline (TMT; fox odour) elicits specific defensive behaviours in rats. <i>Behavioural Brain Research</i> , 2002, 129, 1-16.	2.2	219
241	Contrasting effects of dopamine antagonists and frequency reduction on Fos expression induced by lateral hypothalamic stimulation. <i>Behavioural Brain Research</i> , 2002, 132, 187-201.	2.2	20
242	Increased anxiety in rats after 3,4-methylenedioxyamphetamine: association with serotonin depletion. <i>European Journal of Pharmacology</i> , 2002, 446, 89-96.	3.5	88
243	On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. <i>Psychopharmacology</i> , 2002, 162, 448-450.	3.1	39
244	Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. <i>Life Sciences</i> , 2001, 70, 97-108.	4.3	52
245	Defensive behavior in rats towards predatory odors: a review. <i>Neuroscience and Biobehavioral Reviews</i> , 2001, 25, 597-609.	6.1	388
246	The cardiovascular and behavioral response to cat odor in rats: unconditioned and conditioned effects. <i>Brain Research</i> , 2001, 897, 228-237.	2.2	133
247	The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. <i>Brain Research</i> , 2001, 921, 240-255.	2.2	75
248	Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxyamphetamine (Ecstasy). <i>European Journal of Pharmacology</i> , 2001, 433, 91-99.	3.5	120
249	(±)-3,4-Methylenedioxyamphetamine (MDMA, Ecstasy) increases social interaction in rats. <i>European Journal of Pharmacology</i> , 2000, 408, 41-49.	3.5	98
250	MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. <i>Lancet</i> , The, 2000, 355, 1818-1821.	13.7	86
251	An automated two-choice test of olfactory working memory in the rat: Effect of scopolamine. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2000, 28, 21-31.	1.3	12
252	Beer Consumption in Rats. <i>Alcohol</i> , 1999, 17, 47-56.	1.7	32

#	ARTICLE	IF	CITATIONS
253	Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 1999, 127, 935-940.	5.4	124
254	Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. <i>European Journal of Pharmacology</i> , 1999, 370, 233-240.	3.5	216
255	Dopaminergic modulation of rat pup ultrasonic vocalizations. <i>European Journal of Pharmacology</i> , 1999, 382, 53-67.	3.5	39
256	Low-Dose Midazolam Attenuates Predatory Odor Avoidance in Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1999, 62, 197-201.	2.9	94
257	Habituation of the hiding response to cat odor in rats (<i>Rattus norvegicus</i>).. <i>Journal of Comparative Psychology</i> (Washington, D C: 1983), 1999, 113, 376-387.	0.5	100
258	A comparison of Δ^9 -THC and anandamide induced c-fos expression in the rat forebrain. <i>Brain Research</i> , 1998, 802, 19-26.	2.2	58
259	Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. <i>European Journal of Pharmacology</i> , 1998, 354, 9-16.	3.5	54
260	Possible neural substrates of beer-craving in rats. <i>Neuroscience Letters</i> , 1998, 252, 99-102.	2.1	83
261	Changes in Respiratory Quotient Elicited in Rats by a Conditioned Stimulus Predicting Food. <i>Physiology and Behavior</i> , 1998, 63, 227-232.	2.1	8
262	Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. <i>Brain Research</i> , 1997, 744, 351-357.	2.2	29
263	Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat. <i>Brain Research</i> , 1997, 772, 181-190.	2.2	201
264	Cannabinoid modulation of rat pup ultrasonic vocalizations. <i>European Journal of Pharmacology</i> , 1996, 313, 43-49.	3.5	75
265	Aversive effects of the synthetic cannabinoid CP 55,940 in rats. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 53, 657-664.	2.9	159
266	Using Strawberry Tree WorkbenchMac and Workbench PC software for data acquisition and control in the animal learning laboratory. <i>Behavior Research Methods</i> , 1996, 28, 38-48.	1.3	32
267	Metabolic changes associated with ingestion of different macronutrients and different meal sizes in rats. <i>Physiology and Behavior</i> , 1995, 57, 277-286.	2.1	13
268	Stress-induced changes in respiratory quotient, energy expenditure and locomotor activity in rats: effects of midazolam. <i>Psychopharmacology</i> , 1994, 116, 475-482.	3.1	15
269	Contrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 47, 369-374.	2.9	22
270	Comparison of conditioned taste aversions produced by MDMA and d-amphetamine. <i>Pharmacology Biochemistry and Behavior</i> , 1993, 46, 153-156.	2.9	15

#	ARTICLE	IF	CITATIONS
271	Low and high doses of midazolam differentially affect hypoalgesia in rats conditioned to a heat stressor. <i>Psychopharmacology</i> , 1993, 111, 62-68.	3.1	14
272	Prefrontal cortex $\hat{1}\pm 2$ adrenoceptors and energy balance. <i>Brain Research Bulletin</i> , 1991, 26, 683-691.	3.0	15
273	Metabolic effects obtained from excitatory amino acid stimulation of the sulcal prefrontal cortex. <i>Brain Research</i> , 1990, 529, 1-6.	2.2	28
274	Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus. <i>Brain Research</i> , 1990, 516, 8-14.	2.2	90
275	Stressor-like effects of FG-7142 on medial prefrontal cortex self-stimulation. <i>Brain Research</i> , 1990, 516, 170-174.	2.2	16
276	Footshock stress facilitates self-stimulation of the medial prefrontal cortex but not the lateral hypothalamus in the rat. <i>Brain Research</i> , 1989, 490, 397-403.	2.2	11
277	Controllability of prestimulation of the medial prefrontal cortex determines the facilitation of self-stimulation and kindled seizures. <i>Physiology and Behavior</i> , 1989, 46, 239-245.	2.1	4
278	Antipredator responses toward cat fur in wild brown rats tested in a semi-natural environment. <i>Behavioral Ecology</i> , 0, , .	2.2	9
279	Oxytocin and addiction. , 0, , 270-287.		2